| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.
|
N Engl J Med
|
2002
|
5.39
|
|
2
|
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
|
J Clin Microbiol
|
2004
|
4.70
|
|
3
|
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
|
Clin Infect Dis
|
2009
|
4.59
|
|
4
|
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
|
Clin Infect Dis
|
2013
|
4.14
|
|
5
|
Has antifungal susceptibility testing come of age?
|
Clin Infect Dis
|
2002
|
3.39
|
|
6
|
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
|
Clin Infect Dis
|
2004
|
3.20
|
|
7
|
In Candida albicans, white-opaque switchers are homozygous for mating type.
|
Genetics
|
2002
|
2.96
|
|
8
|
Antimicrobial resistance trends and outbreak frequency in United States hospitals.
|
Clin Infect Dis
|
2003
|
2.54
|
|
9
|
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
|
J Clin Microbiol
|
2005
|
2.26
|
|
10
|
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
|
Antimicrob Agents Chemother
|
2010
|
2.03
|
|
11
|
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.
|
Antimicrob Agents Chemother
|
2011
|
2.01
|
|
12
|
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).
|
Diagn Microbiol Infect Dis
|
2002
|
1.83
|
|
13
|
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
|
Diagn Microbiol Infect Dis
|
2007
|
1.80
|
|
14
|
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.
|
J Clin Microbiol
|
2008
|
1.66
|
|
15
|
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans.
|
Antimicrob Agents Chemother
|
2004
|
1.49
|
|
16
|
Flucytosine resistance is restricted to a single genetic clade of Candida albicans.
|
Antimicrob Agents Chemother
|
2004
|
1.49
|
|
17
|
Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs.
|
J Clin Microbiol
|
2012
|
1.47
|
|
18
|
Homozygosity at the Candida albicans MTL locus associated with azole resistance.
|
Microbiology
|
2002
|
1.43
|
|
19
|
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).
|
J Clin Microbiol
|
2006
|
1.43
|
|
20
|
First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan.
|
Antimicrob Agents Chemother
|
2002
|
1.42
|
|
21
|
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections.
|
J Clin Microbiol
|
2007
|
1.42
|
|
22
|
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.
|
J Clin Microbiol
|
2005
|
1.37
|
|
23
|
Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods.
|
J Clin Microbiol
|
2002
|
1.37
|
|
24
|
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
|
Diagn Microbiol Infect Dis
|
2002
|
1.36
|
|
25
|
Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.
|
Antimicrob Agents Chemother
|
2012
|
1.31
|
|
26
|
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.
|
Antimicrob Agents Chemother
|
2013
|
1.29
|
|
27
|
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.
|
J Acquir Immune Defic Syndr
|
2002
|
1.29
|
|
28
|
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.
|
Emerg Infect Dis
|
2002
|
1.25
|
|
29
|
Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial.
|
Ann Intern Med
|
2005
|
1.23
|
|
30
|
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy.
|
Diagn Microbiol Infect Dis
|
2003
|
1.21
|
|
31
|
Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.
|
J Clin Microbiol
|
2009
|
1.21
|
|
32
|
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates.
|
Fungal Genet Biol
|
2007
|
1.16
|
|
33
|
Rapid detection of antibiotic-resistant organism carriage for infection prevention.
|
Clin Infect Dis
|
2013
|
1.16
|
|
34
|
Dispersal of Staphylococcus aureus into the air associated with a rhinovirus infection.
|
Infect Control Hosp Epidemiol
|
2005
|
1.15
|
|
35
|
Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.
|
Antimicrob Agents Chemother
|
2005
|
1.15
|
|
36
|
Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need.
|
J Clin Microbiol
|
2004
|
1.12
|
|
37
|
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.
|
Antimicrob Agents Chemother
|
2008
|
1.11
|
|
38
|
Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea.
|
Diagn Microbiol Infect Dis
|
2003
|
1.11
|
|
39
|
Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.
|
J Clin Microbiol
|
2008
|
1.10
|
|
40
|
Evidence for recombination in Candida glabrata.
|
Fungal Genet Biol
|
2005
|
1.10
|
|
41
|
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.
|
J Clin Microbiol
|
2003
|
1.09
|
|
42
|
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections.
|
Infect Control Hosp Epidemiol
|
2006
|
1.09
|
|
43
|
Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?
|
Diagn Microbiol Infect Dis
|
2004
|
1.09
|
|
44
|
Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli.
|
Infect Control Hosp Epidemiol
|
2004
|
1.08
|
|
45
|
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
|
Diagn Microbiol Infect Dis
|
2002
|
1.05
|
|
46
|
Modification of dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolates.
|
J Clin Microbiol
|
2002
|
1.05
|
|
47
|
Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance.
|
Antimicrob Agents Chemother
|
2002
|
1.05
|
|
48
|
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
|
Diagn Microbiol Infect Dis
|
2007
|
1.02
|
|
49
|
Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan.
|
Antimicrob Agents Chemother
|
2004
|
0.99
|
|
50
|
Donor-to-host transmission of Candida albicans after corneal transplantation.
|
Am J Ophthalmol
|
2002
|
0.98
|
|
51
|
Nosocomial candidemia: an ounce of prevention is better than a pound of cure.
|
Infect Control Hosp Epidemiol
|
2004
|
0.98
|
|
52
|
Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay.
|
J Clin Microbiol
|
2009
|
0.98
|
|
53
|
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
|
Diagn Microbiol Infect Dis
|
2006
|
0.97
|
|
54
|
Preoperative risk factors for nasal carriage of Staphylococcus aureus.
|
Infect Control Hosp Epidemiol
|
2004
|
0.97
|
|
55
|
Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois.
|
Eukaryot Cell
|
2008
|
0.97
|
|
56
|
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
|
Diagn Microbiol Infect Dis
|
2002
|
0.96
|
|
57
|
Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
|
Diagn Microbiol Infect Dis
|
2009
|
0.95
|
|
58
|
Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state.
|
Infect Control Hosp Epidemiol
|
2006
|
0.95
|
|
59
|
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
|
Diagn Microbiol Infect Dis
|
2008
|
0.95
|
|
60
|
Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.
|
Antimicrob Agents Chemother
|
2011
|
0.95
|
|
61
|
Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis.
|
Int J Med Microbiol
|
2009
|
0.95
|
|
62
|
Clade-related amphotericin B resistance among South African Candida albicans isolates.
|
Diagn Microbiol Infect Dis
|
2005
|
0.94
|
|
63
|
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
|
J Antimicrob Chemother
|
2002
|
0.94
|
|
64
|
Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan.
|
Diagn Microbiol Infect Dis
|
2003
|
0.93
|
|
65
|
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
|
Antimicrob Agents Chemother
|
2011
|
0.93
|
|
66
|
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.
|
Antimicrob Agents Chemother
|
2008
|
0.92
|
|
67
|
Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans.
|
J Clin Microbiol
|
2004
|
0.91
|
|
68
|
Preventing the airborne spread of Staphylococcus aureus by persons with the common cold: effect of surgical scrubs, gowns, and masks.
|
Infect Control Hosp Epidemiol
|
2007
|
0.90
|
|
69
|
Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.
|
J Clin Microbiol
|
2007
|
0.90
|
|
70
|
Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue.
|
Cell Microbiol
|
2006
|
0.89
|
|
71
|
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
|
Diagn Microbiol Infect Dis
|
2008
|
0.89
|
|
72
|
Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.
|
J Clin Microbiol
|
2007
|
0.87
|
|
73
|
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?
|
Diagn Microbiol Infect Dis
|
2002
|
0.86
|
|
74
|
Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
|
J Clin Microbiol
|
2011
|
0.84
|
|
75
|
Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
|
Antimicrob Agents Chemother
|
2011
|
0.83
|
|
76
|
The yeast connection: is Candida linked to breastfeeding associated pain?
|
Am J Obstet Gynecol
|
2007
|
0.83
|
|
77
|
Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.
|
Antimicrob Agents Chemother
|
2010
|
0.81
|
|
78
|
"Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion.
|
J Infect Dis
|
2006
|
0.81
|
|
79
|
Comparison of an automated ribotyping system to restriction endonuclease analysis and pulsed-field gel electrophoresis for differentiating vancomycin-resistant Enterococcus faecium isolates.
|
J Clin Microbiol
|
2002
|
0.81
|
|
80
|
Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus.
|
J Clin Microbiol
|
2010
|
0.80
|
|
81
|
An outbreak of Staphylococcus aureus in a pediatric cardiothoracic surgery unit.
|
Infect Control Hosp Epidemiol
|
2002
|
0.79
|
|
82
|
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
|
Mycopathologia
|
2014
|
0.78
|
|
83
|
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
|
Diagn Microbiol Infect Dis
|
2002
|
0.78
|
|
84
|
Oral beta-lactams in the treatment of acute bacterial rhinosinusitis.
|
Diagn Microbiol Infect Dis
|
2007
|
0.78
|
|
85
|
Airborne dispersal of Staphylococcus aureus associated with symptomatic rhinitis allergica.
|
Ann Intern Med
|
2003
|
0.77
|
|
86
|
Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity).
|
Am J Med
|
2011
|
0.76
|
|
87
|
Presumptive identification of Candida kefyr on levine formulation of eosin methylene blue agar.
|
J Clin Microbiol
|
2002
|
0.75
|
|
88
|
Oral beta-lactams in the treatment of acute otitis media.
|
Diagn Microbiol Infect Dis
|
2007
|
0.75
|
|
89
|
Ronald N. Jones, MD, editor-in-chief, diagnostic microbiology and infectious disease, 1989-2013.
|
Diagn Microbiol Infect Dis
|
2013
|
0.75
|
|
90
|
Airborne dispersal as a novel transmission route of coagulase-negative staphylococci: interaction between coagulase-negative staphylococci and rhinovirus infection.
|
Infect Control Hosp Epidemiol
|
2004
|
0.75
|
|
91
|
Candida albicans isolates from APECED patients show decreased susceptibility to miconazole.
|
Int J Antimicrob Agents
|
2009
|
0.75
|
|
92
|
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.
|
Microb Drug Resist
|
2004
|
0.75
|
|
93
|
A case of recurrent episodes of Candida parapsilosis fungemia.
|
Mycopathologia
|
2006
|
0.75
|
|
94
|
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
|
J Antimicrob Chemother
|
2017
|
0.75
|